TY - JOUR
T1 - Micro-RNA and the features of metabolic syndrome
T2 - A narrative review
AU - Das, Srijit
AU - Mohamed, Isa Naina
AU - Teoh, Seong Lin
AU - Thevaraj, Tarrsini
AU - Nasir, Ku Nurmahirah Ku Ahmad
AU - Zawawi, Azwani
AU - Salim, Hazwan Hazrin
AU - Zhou, Dennis Kheng
N1 - Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2020
Y1 - 2020
N2 - The incidence of metabolic syndrome (MetS) has risen globally. MetS includes a combination of features, i.e. blood glucose impairment, excess abdominal/body fat dyslipidemia and elevated blood pressure. Other than conventional treatment with drugs, the main preventive approaches include lifestyle changes, weight loss, diet control and adequate exercise also proves to be beneficial. MicroRNAs (miRNAs) are small non-coding RNAs that play critical regulatory roles in most biological and pathological processes. In the present review, we discuss various miRNAs which are related to MetS by targeting various organs, including the pancreas, liver, skeletal muscles and adipose tissues. These miRNAs have the effect on insulin production and secretion (miR-9, miR-124a, miR-130a,b, miR152, miR-335, miR-375), insulin resistance (miR-29), adipogenesis (miR-143, miR148a) and lipid metabolism (miR-192). We also discuss the miRNAs as potential biomarkers and future therapeutic targets. This review may be beneficial for molecular biologists and clinicians dealing with MetS.
AB - The incidence of metabolic syndrome (MetS) has risen globally. MetS includes a combination of features, i.e. blood glucose impairment, excess abdominal/body fat dyslipidemia and elevated blood pressure. Other than conventional treatment with drugs, the main preventive approaches include lifestyle changes, weight loss, diet control and adequate exercise also proves to be beneficial. MicroRNAs (miRNAs) are small non-coding RNAs that play critical regulatory roles in most biological and pathological processes. In the present review, we discuss various miRNAs which are related to MetS by targeting various organs, including the pancreas, liver, skeletal muscles and adipose tissues. These miRNAs have the effect on insulin production and secretion (miR-9, miR-124a, miR-130a,b, miR152, miR-335, miR-375), insulin resistance (miR-29), adipogenesis (miR-143, miR148a) and lipid metabolism (miR-192). We also discuss the miRNAs as potential biomarkers and future therapeutic targets. This review may be beneficial for molecular biologists and clinicians dealing with MetS.
KW - Biomarker
KW - Metabolic syndrome
KW - MetS
KW - MiRNA
KW - RNAs
KW - Therapeutic
UR - http://www.scopus.com/inward/record.url?scp=85080065933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080065933&partnerID=8YFLogxK
U2 - 10.2174/1389557520666200122124445
DO - 10.2174/1389557520666200122124445
M3 - Review article
C2 - 31969099
AN - SCOPUS:85080065933
SN - 1389-5575
VL - 20
SP - 626
EP - 635
JO - Anti-Cancer Agents in Medicinal Chemistry
JF - Anti-Cancer Agents in Medicinal Chemistry
IS - 7
ER -